GlassScriptPhysician profile
Waldo Parden Bracy
NPI 1003807744
$3,684.45
in general payments reported to CMS, 2019-2025
37 companies · $932 in 2025
The $932 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $103 · 2022: $428 · 2023: $736 · 2024: $1,170 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,806 · Education: $31.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,806.17 |
| Education | $31.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $495.32 | 2019-2025 | Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $426.98 | 2019-2025 | Trulance, Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $360.17 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $257.34 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $216.74 | 2024-2025 | Omvoh |
| Celgene Corporation | $215.44 | 2022-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $186.02 | 2023-2024 | Dupixent |
| Ardelyx, INC. | $173.44 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $147.77 | 2022-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $139.04 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $112.11 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $107.95 | 2023-2025 | Vegzelma, Yuflyma |
| Aimmune Therapeutics, INC. | $82.18 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $73.82 | 2024-2025 | Rezdiffra, Resmetirom |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.90 | 2023 | Cyltezo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $64.62 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $48.71 | 2022-2024 | Ocaliva |
| Redhill Biopharma INC. | $44.05 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $39.33 | 2022-2024 | Zeposia |
| Allergan, INC. | $39.20 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $36.59 | 2020-2024 | |
| Vivus LLC | $36.38 | 2024-2025 | Pancreaze, Qsymia |
| Pfizer INC. | $31.11 | 2019-2025 | |
| Endogastric Solutions, INC | $28.12 | 2024 | Esophyx |
| Pinnacle Biologics, INC | $27.98 | 2025 | Photofrin |
| Romark Laboratories, Lc | $27.16 | 2020 | |
| Daiichi Sankyo INC. | $27.09 | 2023 | Injectafer |
| Fresenius Kabi USA, LLC | $26.75 | 2024 | Idacio |
| Alnylam Pharmaceuticals INC. | $25.01 | 2025 | |
| Boston Scientific Corporation | $22.34 | 2025 | Varithena Administration Pack |
| Novo Nordisk INC | $20.48 | 2025 | Wegovy |
| Alexion Pharmaceuticals, INC. | $18.78 | 2019 | |
| Amgen INC. | $16.12 | 2022 | |
| Enterra Medical, INC. | $15.67 | 2024 | |
| Organon LLC | $14.96 | 2023 | Hadlima |
| Ethicon US, LLC | $14.78 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waldo Bracy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.